Ascletis Pharma Inc. (HKG:1672)
Hong Kong · Delayed Price · Currency is HKD 16.86
+0.59 (3.63%)
At close: Mar 27, 2026
Ascletis Pharma Revenue
Ascletis Pharma had revenue of 1.08M CNY in the half year ending June 30, 2025, a decrease of -97.68%. This brings the company's revenue in the last twelve months to 2.36M, down -76.57% year-over-year. In the year 2024, Ascletis Pharma had annual revenue of 1.28M, down -97.73%.
Revenue (ttm)
2.36M CNY
Revenue Growth
-76.57%
P/S Ratio
6,664.77
Revenue / Employee
11.37K CNY
Employees
208
Market Cap
17.26B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.28M | -55.31M | -97.73% |
| Dec 31, 2023 | 56.60M | 2.51M | 4.63% |
| Dec 31, 2022 | 54.09M | -22.79M | -29.64% |
| Dec 31, 2021 | 76.88M | 41.88M | 119.64% |
| Dec 31, 2020 | 35.00M | -138.44M | -79.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genscript Biotech | 7.47B |
| Zai Lab | 3.58B |
| InnoCare Pharma | 2.64B |
| Duality Biotherapeutics | 2.06B |
| Everest Medicines | 1.90B |
| Keymed Biosciences | 797.12M |
| Ascentage Pharma Group International | 428.02M |
| CStone Pharmaceuticals | 299.99M |
Ascletis Pharma News
- 17 days ago - Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity - PRNewsWire
- 6 weeks ago - Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development - PRNewsWire
- 2 months ago - Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes - PRNewsWire
- 2 months ago - Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development - PRNewsWire
- 2 months ago - Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes - PRNewsWire
- 3 months ago - Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor - PRNewsWire
- 3 months ago - Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight - PRNewsWire
- 4 months ago - Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development - PRNewsWire